<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cephalosporins</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cephalosporins</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cephalosporins</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alyssa R Letourneau, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based on a shared structural feature, the beta-lactam ring. Cephalosporins are the largest group of beta-lactam antibiotics, cover a broad range of organisms, are generally well-tolerated, are easy to administer, and are thus frequently used.</p><p>The classification, spectrum of activity, and pharmacology of the cephalosporins will be reviewed here.</p><p>The spectrum of activity of cephalosporins combined with beta-lactamase inhibitors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams"</a>.)</p><p>The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics, and the penicillins and other beta-lactam drugs are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/473.html" rel="external">"Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins"</a> and  <a class="medical medical_review" href="/z/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases"</a>.) </p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION OF CEPHALOSPORINS</span><span class="headingEndMark"> — </span>Most of the available cephalosporins are semi-synthetic derivatives of cephalosporin C, a compound with antibacterial activity produced by the fungus <em>Cephalosporium</em>. The closely related cephamycin compounds (derived from <em>Streptomyces</em> spp) are regarded as members of the cephalosporin class. In clinical practice, these antibiotics are grouped into five "generations" based upon their spectrum of activity against aerobic and facultative gram-negative bacilli and gram-positive bacteria (<a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>First generation (eg, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second generation</p><p></p><p class="bulletIndent2">A. Subgroup with activity against <em>Haemophilus influenzae</em> (eg, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>)</p><p class="bulletIndent2">B. Cephamycin subgroup with activity against <em>Bacteroides</em> spp (eg, <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> and <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third generation</p><p></p><p class="bulletIndent2">A. Subgroup with broad gram-negative activity but poor activity against <em>Pseudomonas aeruginosa</em> (eg, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) </p><p class="bulletIndent2">B. Subgroup with broad gram-negative activity including good activity against <em>Pseudomonas aeruginosa</em> (eg, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fourth generation (eg, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fifth generation (eg, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>)</p><p></p><p>Additional advanced cephalosporins include a siderophore cephalosporin (<a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>) and cephalosporin combinations with beta-lactamase inhibitors. (See <a class="local">'Other cephalosporins'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">SPECTRUM OF ACTIVITY AND CLINICAL USE</span></p><p class="headingAnchor" id="H2999651"><span class="h2">Parenteral agents</span></p><p class="headingAnchor" id="H5"><span class="h3">First generation</span><span class="headingEndMark"> — </span>Cephalothin is the oldest of the first-generation cephalosporins and was previously used as the prototype of this group. Cephalothin was active against most gram-positive cocci (including penicillinase-producing staphylococci), but did not have clinically useful activity against enterococci, <em>Listeria</em>, methicillin-resistant staphylococci [<a href="#rid1">1</a>], or penicillin-resistant pneumococci [<a href="#rid2">2-4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3153.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology"</a> and  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>.)</p><p>Cephalothin was active against most strains of <em>Escherichia coli</em>, <em>Proteus mirabilis</em>, and <em>Klebsiella pneumoniae</em>, but had little activity against indole-positive <em>Proteus</em>, <em>Enterobacter</em>, <em>Serratia</em>, and the nonenteric gram-negative bacilli such as <em>Acinetobacter</em> spp and <em>Pseudomonas aeruginosa</em>. Gram-negative cocci (such as the gonococcus and meningococcus) and <em>H. influenzae</em> were generally resistant. Cephalothin was active against most of the common anaerobic pathogens, with certain exceptions such as <em>Bacteroides</em> species, particularly <em>B. fragilis</em>.</p><p><a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a> has a similar spectrum of activity to cephalothin, is available worldwide, and is now the only parenteral first-generation cephalosporin available in the United States. Cefazolin achieves substantially higher serum levels than cephalothin, and has a longer half-life of elimination. Cefazolin is less stable than cephalothin in vitro to the type A penicillinase of staphylococci [<a href="#rid5">5</a>]; the relevance of this difference for clinical therapy, however, is not certain.</p><p class="headingAnchor" id="H6"><span class="h3">Second generation</span><span class="headingEndMark"> — </span>Compared with first-generation agents, the second-generation cephalosporins are somewhat less active against staphylococci. In contrast, they have greater activity against certain gram-negative bacilli; specifically, one subgroup of second-generation cephalosporins has enhanced activity against <em>H. influenzae</em> and another, the cephamycins, has enhanced activity against <em>Bacteroides</em>.</p><p class="headingAnchor" id="H7"><span class="h4">Activity against Haemophilus influenzae</span><span class="headingEndMark"> — </span>In the first subgroup, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a> is available parenterally and orally, and is more active than <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> in vitro against strains of <em>Enterobacter</em> and indole-positive <em>Proteus</em>. However, this agent induces the AmpC chromosomal beta-lactamases of these organisms, leading to resistance and failures of clinical therapy [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Mechanisms of bacterial resistance'</a>.)</p><p><a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">Cefuroxime</a> is also more active than <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> against <em>H. influenzae</em>, and cefuroxime is quite stable to the TEM beta-lactamase in ampicillin-resistant strains. Although cefuroxime is approved for the therapy of <em>H. influenzae</em> meningitis, delayed responses and treatment failures have occurred, and a third-generation cephalosporin is now preferred for therapy of meningitis due to ampicillin-resistant strains [<a href="#rid7">7</a>]. Cefuroxime is also highly active against beta-lactamase-producing <em>Moraxella catarrhalis</em>.</p><p class="headingAnchor" id="H8"><span class="h4">Cephamycin subgroup (active against Bacteroides)</span><span class="headingEndMark"> — </span>The cephamycin subgroup of the second-generation cephalosporins includes <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> and <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>. This subgroup is active against most strains of <em>E. coli</em>, <em>P. mirabilis</em>, and <em>Klebsiella</em>, like the first-generation cephalosporins. The cephamycins are quite stable to many plasmid-mediated beta-lactamases, but the activity of this group against <em>Enterobacter</em> and indole-positive <em>Proteus</em> is limited by induction of chromosomal cephalosporinases of these species and selection of stably derepressed mutants [<a href="#rid6">6</a>].</p><p>Unlike the first-generation cephalosporins, the cephamycins are active against many strains of <em>Bacteroides</em>. The combination of activity against common aerobic and facultative gram-negative bacilli plus <em>Bacteroides</em> has led to the use of the cephamycins in the prophylaxis and therapy of infections in the abdominal and pelvic cavities (where these organisms predominate) [<a href="#rid8">8</a>]. The cephamycins have no clear advantages over the first-generation cephalosporins for infections outside of the abdominal and pelvic areas.</p><p>For the <em>Bacteroides fragilis</em> group, overall resistance rates to cephamycins range from 10 to 80 percent, depending on the specific subspecies [<a href="#rid9">9,10</a>]. For comparison, resistance rates to other antibiotics with anaerobic coverage are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5520.html" rel="external">"Anaerobic bacterial infections"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Third generation</span><span class="headingEndMark"> — </span>The third-generation cephalosporin class [<a href="#rid11">11</a>] is marked by stability to the common beta-lactamases of gram-negative bacilli, and these compounds are highly active against Enterobacterales (<em>E. coli</em>, <em>Proteus mirabilis</em>, indole-positive <em>Proteus</em>, <em>Klebsiella</em>, <em>Enterobacter</em>, <em>Serratia</em>, <em>Citrobacter</em>), <em>Neisseria</em>, and <em>H. influenzae</em>. They are the therapy of choice for gram-negative meningitis due to susceptible Enterobacterales. Third-generation cephalosporins may also be useful alternatives to the aminoglycosides in treating gram-negative infections resistant to other beta-lactams, particularly in the patient with renal dysfunction. However, mutants of <em>Enterobacter</em>, indole-positive <em>Proteus</em>, <em>Serratia</em>, and <em>Citrobacter</em>, with stable derepression of the chromosomal beta-lactamase, are resistant to these antibiotics [<a href="#rid6">6,12</a>]. Even if these organisms (<em>Enterobacter</em>, indole-positive <em>Proteus</em>, <em>Serratia</em>, and <em>Citrobacter</em>) test susceptible to cephalosporins, use of a third-generation cephalosporin as a single agent for treatment of serious infections due to these bacteria can lead to the emergence of resistance during therapy.</p><p>The third-generation cephalosporins are less active against most gram-positive organisms than the first-generation cephalosporins and are inactive against enterococci, <em>Listeria</em>, methicillin-resistant staphylococci, and <em>Acinetobacter</em>. <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">Cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> are usually active against pneumococci with intermediate susceptibility to penicillin, but strains fully resistant to penicillin are often resistant to the third-generation cephalosporins as well. (See  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>.)</p><p>Treatment with third-generation cephalosporins may be complicated by superinfection (particularly with enterococci or <em>Candida</em>) or by the emergence of resistance on therapy (particularly when used as single agents for <em>Enterobacter</em>, indole-positive <em>Proteus</em>, or <em>P. aeruginosa</em> infections) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H10"><span class="h4">Poor activity against Pseudomonas</span><span class="headingEndMark"> — </span>One subgroup of the third-generation cephalosporins, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, has poor activity against <em>P. aeruginosa</em>. Within this subgroup, cefotaxime has the shortest serum half-life (1 hour) because of partial metabolism in the liver to desacetyl-cefotaxime. However, this metabolite also has antibacterial activity and a longer half-life in serum (1.7 hours), allowing dosing every six hours.</p><p><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> has the longest serum half-life of this group (6.4 hours) and can be administered once or twice a day. Ceftriaxone has been particularly recommended for the therapy of penicillin-resistant gonorrhea, Lyme disease involving the central nervous system or joints, meningitis due to ampicillin-resistant <em>H. influenzae</em>, and meningitis in children [<a href="#rid7">7,14</a>]. One of the complications of ceftriaxone therapy, however, has been the formation in the biliary tract of "sludge" composed of ceftriaxone crystals, causing the syndrome of biliary pseudolithiasis [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H11"><span class="h4">Activity against Pseudomonas</span><span class="headingEndMark"> — </span>The other of the third-generation cephalosporins, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, has activity against <em>P. aeruginosa</em>. Ceftazidime is quite stable to the common plasmid-mediated beta-lactamases and is highly active against Enterobacterales, <em>Neisseria</em>, and <em>H. influenzae</em>. Ceftazidime is also particularly active against <em>P. aeruginosa</em> and is an effective therapy for serious infections due to <em>P. aeruginosa</em> when the organism is resistant to the antipseudomonal penicillins or the patient is allergic to penicillin. In addition, it is effective therapy for meningitis caused by <em>P. aeruginosa</em>. As with the antipseudomonal penicillins, however, ceftazidime should generally be given at least initially in combination with an aminoglycoside for treatment of serious <em>P. aeruginosa</em> infection, when susceptibilities are unknown. Ceftazidime has poor activity against gram-positive organisms and should be reserved for use in infections proven or highly suspected to be due to <em>P. aeruginosa</em>.</p><p class="headingAnchor" id="H12"><span class="h3">Fourth generation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> is the fourth-generation cephalosporin currently available. It has a positively charged quaternary ammonium attached to the dihydrothiazone ring, which results in better penetration through the outer membrane of gram-negative bacteria and a lower affinity than the third-generation cephalosporins for certain chromosomal beta-lactamases of gram-negative bacilli.</p><p><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> has activity similar to that of <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> against pneumococci (including penicillin-intermediate strains) and methicillin-sensitive <em>S. aureus</em>. Like the earlier third-generation agents, it is active against the Enterobacterales, <em>Neisseria</em>, and <em>H. influenzae</em> but has greater activity against the gram-negative enterics that have a broad-spectrum, inducible, chromosomal AmpC beta-lactamase (<em>Enterobacter</em>, indole-positive <em>Proteus</em>, <em>Citrobacter</em>, and <em>Serratia</em>) [<a href="#rid16">16</a>]. The role of cefepime in therapy of infections due to stably-derepressed mutants of these organisms has not yet been fully defined, but some data suggest that it may be effective [<a href="#rid17">17,18</a>]. In a study of 96 patients with infections due to laboratory-confirmed AmpC beta-lactamase-producing organisms, 96 percent of the isolates were susceptible to cefepime [<a href="#rid17">17</a>]. Among patients who received cefepime, the 30-day mortality rate and duration of hospitalization were similar to those observed in a matched subset of patients who received <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. </p><p><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> is as active as <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> for <em>P.</em> <em>aeruginosa</em>, and is active against some ceftazidime-resistant isolates. As with the antipseudomonal penicillins, cefepime should generally be given in combination with an aminoglycoside for treatment of serious <em>P. aeruginosa</em> infection when susceptibilities are unknown. Accumulated data suggest it can be used for meningitis caused by susceptible gram-negative bacilli [<a href="#rid19">19</a>]. It is not currently recommended for prophylactic use in surgery. <em>Acinetobacter</em> isolates are frequently resistant to cefepime. </p><p>Despite these potential advantages over third-generation cephalosporins, especially against organisms with inducible, chromosomal resistance, comparative trials of third- and fourth-generation cephalosporins have not yet been performed.</p><p>A review by the United States Food and Drug Administration (FDA) of <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> safety data was initiated in 2007 following findings of a meta-analysis that raised concern regarding increased all-cause mortality associated with cefepime use (risk ratio 1.26, 95% CI 1.08-1.49) [<a href="#rid20">20</a>]. The FDA reviewed these study data, conducted additional analyses based on other data, and determined that the data do not indicate a higher rate of death in cefepime-treated patients [<a href="#rid21">21</a>]. Cefepime remains an appropriate therapy for its approved indications [<a href="#rid22">22</a>].</p><p>Treatment with <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> may be complicated by superinfection (particularly with enterococci or <em>Candida</em>) [<a href="#rid13">13</a>]. Cefepime use also carries a risk of seizures (specifically nonconvulsive status epilepticus), particularly in patients with renal failure for whom the dose is not appropriately reduced [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Neurologic reactions'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Fifth generation</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> – This is a fifth-generation cephalosporin whose active metabolite has a spectrum of in vitro activity similar to that of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> but with improved gram-positive activity. In particular, ceftaroline has higher affinity for penicillin-binding protein 2a (PBP2a) in methicillin-resistant staphylococci, and has activity against MRSA, as well as vancomycin-intermediate <em>Staphylococcus aureus</em> (VISA) and hetero-VISA. In addition, ceftaroline has activity for <em>Streptococcus pneumoniae</em> that is intermediate or resistant to penicillin or ceftriaxone. Ceftaroline is not active for enterococci nor against AmpC-overproducing or ESBL-producing Enterobacterales, <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter baumannii</em>, or <em>B. fragilis</em>. Randomized, double-blind controlled clinical trials have suggested that ceftaroline is noninferior to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> for treatment of complicated skin and soft tissue infections including those due to MRSA, and to ceftriaxone for therapy of community-acquired pneumonia [<a href="#rid24">24-26</a>]. For MRSA bacteremia, limited observational data suggest efficacy as monotherapy or as part of combination therapy with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> [<a href="#rid27">27-30</a>]. Efficacy is not yet known for hospital-acquired MRSA pneumonia. Clinical use of ceftaroline is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Methicillin-resistant S. aureus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> – This is a cephalosporin available in Canada and some European countries (but not the United States) that is also capable of binding to PBP2a, the protein conferring <em>S. aureus</em> resistance to beta-lactam antibiotics [<a href="#rid31">31</a>]. It can also bind PBP2x in penicillin-resistant <em>S. pneumoniae</em>. It has in vitro activity similar to that of <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> against Enterobacterales; it also has activity against enterococci [<a href="#rid32">32,33</a>]. In addition, ceftobiprole appears to have a low potential for selection of resistance [<a href="#rid34">34</a>].</p><p></p><p>Clinical trial data on these agents for use in MRSA infections are detailed separately. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections", section on 'Ceftaroline (and ceftobiprole)'</a>.)</p><p class="headingAnchor" id="H1051964503"><span class="h3">Other cephalosporins</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">Cefiderocol</a> – This siderophore cephalosporin has activity against multidrug-resistant gram-negative bacteria, including extended-spectrum beta-lactamase- or carbapenemase-producing organisms and multidrug-resistant <em>P. aeruginosa</em>, <em>A. baumannii</em>, <em>Stenotrophomonas maltophilia</em>, and <em>Burkholderia cepacia</em>. In addition to enhanced stability against beta-lactamases, it has a novel mechanism for transport across the outer membrane that can overcome the effect of membrane permeability mutations, as seen in <em>P. aeruginosa </em>[<a href="#rid35">35</a>]. Cefiderocol is thought to have poor gram-positive and anaerobic activity.</p><p></p><p class="bulletIndent1">In the United States, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> has been approved by the Food and Drug Administration for use in adults with complicated urinary tract infections (UTIs; including pyelonephritis) and hospital-acquired or ventilator-associated pneumonia due to otherwise highly resistant gram-negative bacteria when there are no alternative treatment regimens [<a href="#rid36">36-38</a>]. Randomized, double-blind trials have reported similar outcomes between cefiderocol and carbapenems for patients with complicated UTIs or nosocomial pneumonia due to gram-negative pathogens [<a href="#rid39">39,40</a>]. Additionally, a randomized, open-label multi-national trial of patients with carbapenem-resistant gram-negative infections (ie, pneumonia, bacteremia or sepsis, complicated UTI) found similar clinical and microbiologic cure rates with cefiderocol versus best available therapy. There were more deaths in the cefiderocol group, but the significance of this finding is uncertain and may have been influenced by the heterogeneous patient-population and high proportion of <em>A. baumannii</em> infections among those who died [<a href="#rid41">41</a>].</p><p></p><p>Combinations of cephalosporins with beta-lactamase inhibitors are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftolozane-tazobactam'</a> and  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftazidime-avibactam'</a>.) </p><p class="headingAnchor" id="H14"><span class="h2">Oral agents</span><span class="headingEndMark"> — </span>Cephalosporins available for oral use include <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a>, <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a>, <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">cefaclor</a>, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a> axetil, <a class="drug drug_general" data-topicid="9225" href="/z/d/drug information/9225.html" rel="external">cefprozil</a>, <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a>, <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a> proxetil, <a class="drug drug_general" data-topicid="9227" href="/z/d/drug information/9227.html" rel="external">ceftibuten</a>, and <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">cefdinir</a> (<a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">table 1</a>).</p><p>Among the first-generation cephalosporins available for oral use, <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a> has a longer serum half-life than <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> and is generally given in a dose of 500 to 1000 mg every 12 hours. The oral cephalosporins are poorly active against penicillin-resistant pneumococci [<a href="#rid2">2</a>].</p><p>The oral second-generation cephalosporins, <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">cefaclor</a>, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a> axetil, and <a class="drug drug_general" data-topicid="9225" href="/z/d/drug information/9225.html" rel="external">cefprozil</a>, have improved activity against <em>H. influenzae</em> compared with the first-generation oral cephalosporins and may be useful in treating otitis, sinusitis, and respiratory tract infections.</p><p>The oral third-generation cephalosporins, <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a>, <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a> proxetil, <a class="drug drug_general" data-topicid="9227" href="/z/d/drug information/9227.html" rel="external">ceftibuten</a>, and <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">cefdinir</a> are active against streptococci, <em>H. influenzae</em> (including beta-lactamase producing strains), and <em>M. catarrhalis</em>. They are more active than the other oral cephalosporins against enteric gram-negative bacilli, including <em>E. coli</em>, <em>P. mirabilis</em>, and <em>Klebsiella</em>. However, they have poor activity against most strains of <em>Enterobacter</em>, <em>Acinetobacter</em>, <em>P. aeruginosa</em>, and the anaerobes. Cefixime and ceftibuten have little activity against staphylococci, but cefpodoxime proxetil and cefdinir have more activity. Ceftibuten is also only weakly active against pneumococci. Its spectrum of activity is otherwise similar to those of cefdinir and cefpodoxime.</p><p>These antibiotics are relatively stable to many plasmid-mediated beta-lactamases but are much less stable to common chromosomally-mediated cephalosporinases. Although these antibiotics are promoted as oral third-generation cephalosporins, they are <strong>less</strong> active against the enteric gram-negative bacilli than the parenteral third- or fourth-generation cephalosporins. These antibiotics are recommended as therapy for otitis media, upper and lower respiratory tract infections, and UTIs (<a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a>, <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a>, and <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">cefdinir</a>). These indications are shared with the oral second-generation cephalosporins, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, and <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. Cefixime and <a class="drug drug_general" data-topicid="9227" href="/z/d/drug information/9227.html" rel="external">ceftibuten</a> have little or no activity against staphylococci in contrast to some of these other agents.</p><p class="headingAnchor" id="H2999961"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>Many of the available parenteral cephalosporins have short serum half-lives (generally one hour or less) and should be administered on an every four hour basis when treating serious systemic infections in patients with normal renal function (<a class="graphic graphic_table graphicRef58411" href="/z/d/graphic/58411.html" rel="external">table 2</a>). Certain cephalosporins have longer serum half-lives and may be dosed less frequently (eg, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> Q8h and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> Q24h). All of the cephalosporins except ceftriaxone require dose modification in the presence of severe renal failure (<a class="graphic graphic_table graphicRef58411" href="/z/d/graphic/58411.html" rel="external">table 2</a>). </p><p>All of the cephalosporins achieve therapeutic levels in pleural, pericardial, peritoneal, and synovial fluids, and urine. Biliary concentrations exceed serum levels (in the absence of obstruction) and are particularly high for <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>.</p><p>First- and second-generation cephalosporins (except <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>) penetrate the cerebrospinal fluid (CSF) barrier poorly and should not be used to treat infections of the central nervous system. The third-generation cephalosporins achieve much more reliable CSF levels in patients with meningeal irritation. Peak CSF concentrations of several cephalosporins given at meningeal doses are shown in the table (<a class="graphic graphic_table graphicRef62934" href="/z/d/graphic/62934.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">Cefotaxime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, and <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> are approved for the treatment of bacterial meningitis.</p><p>Fatal reactions due to calcium-ceftriaxone precipitates in the lungs and kidneys of neonates have been reported. <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> should not be reconstituted or mixed with a calcium-containing product (eg, Ringer's or Hartmann's solution or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>). In addition, ceftriaxone should be avoided in infants aged ≤28 days if they are receiving or expected to receive intravenous calcium-containing products. However, ceftriaxone and calcium-containing products may be used concomitantly in patients aged &gt;28 days, provided that the infusion lines are thoroughly flushed between infusions [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H19315799"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of parenteral cephalosporins</strong> – In clinical practice, cephalosporins are grouped into five "generations" based upon their spectrum of activity against aerobic and facultative gram-negative bacilli and gram-positive bacteria (<a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral cephalosporins</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First-generation</strong> – These cephalosporins, including <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, are active against most gram-positive cocci except for enterococci, methicillin-resistant staphylococci, and penicillin-resistant pneumococci. They are also active against most strains of <em>Escherichia coli</em>, <em>Proteus mirabilis</em>, and <em>Klebsiella pneumoniae</em>. (See <a class="local">'First generation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second-generation</strong> – This group includes two subgroups. One subgroup has activity against <em>Haemophilus influenzae</em> and <em>Moraxella catarrhalis</em>. The other subgroup consists of the cephamycins, which are active against many strains of <em>Bacteroides</em>. (See <a class="local">'Second generation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Third-generation</strong> – Members of this group have less activity against most gram-positive organisms than first-generation agents but are highly active against Enterobacterales, <em>Neisseria</em>, and <em>H. influenzae</em>. <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">Ceftazidime</a> is also active against <em>Pseudomonas</em> <em>aeruginosa</em>. (See <a class="local">'Third generation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fourth generation</strong> – The only fourth-generation cephalosporin, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, has similar activity as the third-generation cephalosporins and also includes activity against <em>P. aeruginosa. </em>It has greater activity than earlier generations against enteric gram-negative bacilli that have an inducible chromosomal beta-lactamase. (See <a class="local">'Fourth generation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fifth generation</strong> – The novel fifth-generation cephalosporin, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, has activity against methicillin-resistant staphylococci, penicillin-resistant pneumococci, and enteric gram-negative rods. It is not active against extended-spectrum beta-lactamase (ESBL)- or Amp-C-producing Enterobacterales, <em>P. aeruginosa</em>, <em>Acinetobacter baumannii</em>, or <em>Bacteroides fragilis. </em>(See <a class="local">'Fifth generation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Siderophore cephalosporin</strong> – A novel siderophore cephalosporin, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, does not belong to any of the above groups. It has activity against multidrug-resistant gram-negative bacteria, including ESBL- or carbapenemase-producing organisms and multidrug-resistant <em>P. aeruginosa</em>, <em>A. baumannii</em>, <em>Stenotrophomonas maltophilia</em>, and <em>Burkholderia cepacia</em>. (See <a class="local">'Other cephalosporins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral dosing and administration</strong> – Many of the available parenteral cephalosporins have short serum half-lives and require frequent administration. All of the cephalosporins except <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> require dose modification in the presence of severe renal failure. Doses are listed in the table (<a class="graphic graphic_table graphicRef58411" href="/z/d/graphic/58411.html" rel="external">table 2</a>). (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue penetration of parenteral formulations</strong> – All of the parenteral cephalosporins achieve therapeutic levels in pleural, pericardial, peritoneal, and synovial fluids, and urine. First- and second-generation cephalosporins enter into cerebrospinal fluid (CSF) poorly. Third-generation cephalosporins achieve more reliable CSF levels in patients with meningeal irritation (<a class="graphic graphic_table graphicRef62934" href="/z/d/graphic/62934.html" rel="external">table 3</a>). (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral cephalosporins</strong> – These are also divided into different generations, and their spectra of activity generally mirror those parenteral agents of the corresponding generation (<a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">table 1</a>). However, oral third-generation drugs are less active against enteric gram-negative bacteria than the parenteral third-generation cephalosporins. Second- and third-generation oral cephalosporins have similar indications, namely otitis media, respiratory tract infections, and urinary tract infections (UTIs). (See <a class="local">'Oral agents'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.</a></li><li><a class="nounderline abstract_t">Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377.</a></li><li><a class="nounderline abstract_t">Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917.</a></li><li><a class="nounderline abstract_t">Sabath LD. Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins. Antimicrob Agents Chemother 1989; 33:407.</a></li><li><a class="nounderline abstract_t">Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.</a></li><li><a class="nounderline abstract_t">Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.</a></li><li><a class="nounderline abstract_t">Bohnen JM, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127:83.</a></li><li><a class="nounderline abstract_t">Snydman DR, McDermott L, Cuchural GJ Jr, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23 Suppl 1:S54.</a></li><li><a class="nounderline abstract_t">Jean S, Wallace MJ, Dantas G, Burnham CD. Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group. J Clin Microbiol 2022; 60:e0236120.</a></li><li><a class="nounderline abstract_t">Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79:705.</a></li><li><a class="nounderline abstract_t">Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995; 21:1107.</a></li><li><a class="nounderline abstract_t">Lynch JP 3rd. Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit. Semin Respir Infect 1993; 8:268.</a></li><li><a class="nounderline abstract_t">Steere AC. Lyme disease. N Engl J Med 1989; 321:586.</a></li><li><a class="nounderline abstract_t">Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.</a></li><li><a class="nounderline abstract_t">Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454.</a></li><li><a class="nounderline abstract_t">Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781.</a></li><li><a class="nounderline abstract_t">Siedner MJ, Galar A, Guzmán-Suarez BB, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 2014; 58:1554.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338.</a></li><li><a class="nounderline abstract_t">Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:381.</a></li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm167427.htm (Accessed on June 18, 2009).</li><li class="breakAll">FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, June 26, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm309661.htm (Accessed on June 27, 2012).</li><li><a class="nounderline abstract_t">Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641.</a></li><li><a class="nounderline abstract_t">File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.</a></li><li><a class="nounderline abstract_t">File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55 Suppl 3:S173.</a></li><li><a class="nounderline abstract_t">Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis 2022; 9:ofab606.</a></li><li><a class="nounderline abstract_t">Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents 2019; 53:644.</a></li><li><a class="nounderline abstract_t">McCreary EK, Kullar R, Geriak M, et al. Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. Open Forum Infect Dis 2020; 7:ofz538.</a></li><li><a class="nounderline abstract_t">Geriak M, Haddad F, Rizvi K, et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13 Suppl 2:25.</a></li><li><a class="nounderline abstract_t">Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16:419.</a></li><li><a class="nounderline abstract_t">Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821.</a></li><li><a class="nounderline abstract_t">Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 2019; 79:271.</a></li><li><a class="nounderline abstract_t">Stevens RW, Clancy M. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report. Pharmacotherapy 2019; 39:1113.</a></li><li><a class="nounderline abstract_t">Edgeworth JD, Merante D, Patel S, et al. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2019; 68:1932.</a></li><li class="breakAll">Cefiderocol. US Food and Drug Administration (FDA) approved product information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf (Accessed on September 29, 2020).</li><li><a class="nounderline abstract_t">Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18:1319.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021; 21:213.</a></li><li><a class="nounderline abstract_t">Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm (Accessed on June 08, 2009).</li></ol></div><div id="topicVersionRevision">Topic 480 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452155" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994784" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antibiotic resistance in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8028618" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136262" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658789" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236486" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403654" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734854" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8953108" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35700139" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791418" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Third-generation cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589129" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7938924" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2668764" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lyme disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227290" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879764" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759352" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The use of cefepime for treating AmpCβ-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647022" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448937" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of cefepime: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624065" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Meta-analysis of a possible signal of increased mortality associated with cefepime use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624065" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meta-analysis of a possible signal of increased mortality associated with cefepime use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624065" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Meta-analysis of a possible signal of increased mortality associated with cefepime use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695801" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067350" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903949" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Summary of ceftaroline fosamil clinical trial studies and clinical safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35146040" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711613" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31938716" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858203" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488373" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371191" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963275" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189100" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712199" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31550054" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418554" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418554" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509675" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058798" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058795" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
